Skip to main content
Contact Us
Subscribe
E-Edition
42°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by MacroGenics, Inc.
MacroGenics to Participate in Upcoming Investor Conferences
November 06, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Leadership Transition
October 30, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call
October 29, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
September 15, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024
September 08, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Provides Vobramitamab Duocarmazine Update
July 30, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte
July 30, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics to Participate in Upcoming Investor Conference
June 11, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics to Participate in Upcoming Investor Conferences
May 13, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call
May 03, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
April 03, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics to Participate in Upcoming Investor Conferences
March 01, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call
February 27, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics to Participate in Upcoming Investor Conference
February 02, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics to Participate in Upcoming Investor Conference
January 08, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics to Participate in Upcoming Investor Conferences
November 02, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Date of Third Quarter 2023 Financial Results Conference Call
October 31, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Achievement of $15 Million Milestone Related to Gilead’s Nomination of a Bispecific Research Program
September 05, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics to Participate in Upcoming Investor Conferences
August 31, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Date of Second Quarter 2023 Financial Results Conference Call
July 31, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Date of First Quarter 2023 Financial Results Conference Call
May 04, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics to Participate in Upcoming Investor Conferences
April 24, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ™ (retifanlimab-dlwr)
March 22, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million
March 08, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call
March 07, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics to Participate in Upcoming Investor Conferences
March 02, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients with Metastatic Castration-Resistant Prostate Cancer to be Presented at ASCO Genitourinary Cancers Symposium
February 13, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics to Participate in Upcoming Investor Conferences
February 06, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors
January 04, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
